
Mark W Stolar MD
Diabetes, Lipid Metabolism
Associate Professor, Medicine, Northwestern University Medical School
Join to view full profile
3707 Doty RdSte EWoodstock, IL 60098
Phone+1 815-338-6600
Fax+1 815-337-1980
Dr. Stolar is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Endocrinology, Diabetes, and Metabolism, 1982 - 1984
Advocate Health Care/Advocate Lutheran General HospitalResidency, Internal Medicine, 1979 - 1982
University of Illinois College of MedicineClass of 1979
Certifications & Licensure
FL State Medical License 2024 - Present
IL State Medical License 1981 - 2029
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks, eClinicalWorks, LLC, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Northwestern Meaningful Use Data Warehouse Application for Eligible Providers, Northwestern University, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
Publications & Presentations
PubMed
- 1 citationsSGLT2-inhibitors and asthma outcomes in type 2 diabetes: Insights from a large multicenter study.A B M Nasibul Alam, Natasha Gill, Maram AlAshoor, Iman Cherif, Mark Stolar
Respiratory Medicine. 2025-11-01 - 12 citationsCOVID-19-Induced Diabetic Ketoacidosis in an Adult with Latent Autoimmune DiabetesYetunde B Omotosho, Grace W Ying, Mark W. Stolar, Arvin Junn P Mallari
Cureus. 2021-01-13 - 8 citationsComparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes.Mark W. Stolar, Michael Grimm, Steve Chen
Diabetes, Metabolic Syndrome and Obesity. 2013-11-22
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: